Non-alcoholic Fatty Liver Diseases (NAFLD) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions:   NAFLD;   MASLD;   Mild Inflammatory Context Intervention:   Dietary Supplement: TOTUM-448 Sponsors:   Valbiotis;   Clinic'n'Cell;   University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One;   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two;   Drug: Placebo - Study Part One;   Drug: Placebo - Study Part Two Sponsor:   ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions:   NAFLD;   MASLD;   Mild Inflammatory Context Intervention:   Dietary Supplement: TOTUM-448 Sponsors:   Valbiotis;   Clinic'n'Cell;   University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One;   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two;   Drug: Placebo - Study Part One;   Drug: Placebo - Study Part Two Sponsor:   ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions:   NAFLD;   MASLD;   Mild Inflammatory Context Intervention:   Dietary Supplement: TOTUM-448 Sponsors:   Valbiotis;   Clinic'n'Cell;   University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One;   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two;   Drug: Placebo - Study Part One;   Drug: Placebo - Study Part Two Sponsor:   ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions:   NAFLD;   MASLD;   Mild Inflammatory Context Intervention:   Dietary Supplement: TOTUM-448 Sponsors:   Valbiotis;   Clinic'n'Cell;   University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One;   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two;   Drug: Placebo - Study Part One;   Drug: Placebo - Study Part Two Sponsor:   ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions:   NAFLD;   MASLD;   Mild Inflammatory Context Intervention:   Dietary Supplement: TOTUM-448 Sponsors:   Valbiotis;   Clinic'n'Cell;   University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One;   Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two;   Drug: Placebo - Study Part One;   Drug: Placebo - Study Part Two Sponsor:   ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions:   NAFLD;   MASLD;   Mild Inflammatory Context Intervention:   Dietary Supplement: TOTUM-448 Sponsors:   Valbiotis;   Clinic'n'Cell;   University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Conditions: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsors: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions: NAFLD; MASLD; Mild Inflammatory Context Interventions: Dietary Supplement: TOTUM-448 Sponsors: Valbiotis; Clinic ' n ' Cell; University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials